Take Homes in Breast Cancer
Take Homes in Breast Cancer
Source/Disclosures
Source:


Disclosures: Abraham reports no relevant financial disclosures
June 24, 2020
1 min watch
Save

VIDEO: Radiation, trastuzumab combination ‘not recommended’ for HER2+ DCIS

Source/Disclosures
Source:


Disclosures: Abraham reports no relevant financial disclosures
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, Jame Abraham, MD, director of breast oncology at Cleveland Clinic, highlighted the results from the NSABP B-43 trial that included radiation therapy efficacy with or without trastuzumab in women with ductal carcinoma in situ who have undergone lumpectomy.

Abraham discussed details of the study, specifically the dosing and efficacy of trastuzumab for women with HER2-postive ductal carcinoma in situ (DCIS).

“The addition of trastuzumab to radiation treatment did not see the primary objective of the protocol, but it did achieve a ... statistically non-significant reduction of 19% ipsilateral recurrence. So, addition of trastuzumab to radiation treatment in HER2-positive DCIS is not recommended, based upon this study,” Abraham concluded.

  • Cobleigh, MA et al. Abstract TPS666. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.